Tβ4 offers both neurorestoration and neuroprotection after TBI

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") reported that data showing that Thymosin beta 4 (Tβ4) "provides both neuroprotection and neurorestoration after traumatic brain injury (TBI)," was published in the current (May 2012) edition of the Journal of Neurosurgery, 116:1081-1092.    

As reported in the epub edition of the journal, the aims of the study were to test if Tβ4 treatment initiated 6 hours after traumatic brain injury in rats reduces brain damage and improves functional recovery. According to the research team, "Compared with saline administration, Tβ4 treatment initiated 6 hours postinjury significantly improved sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell loss, and enhanced cell proliferation and neurogenesis in the injured hippocampus. Thymosin β4 treatment initiated 6 hours postinjury provides both neuroprotection and neurorestoration after TBI, indicating that Tβ4 has promising therapeutic potential in patients with TBI."

"These results are extremely encouraging and are consistent with results of Tβ4 administration in other Central nervous system injuries, as well as in cardiovascular injury models. Moreover, the reduction of brain damage, improved motor function, and regeneration of injured brain tissue, when Tβ4 is administered 6 hours after TBI, suggest that it could potentially be useful for the treatment of brain traumas seen in the military, the workplace and in contact sports," stated Dr. Allan Goldstein, Professor and Chairman Emeritus, Department of Biochemistry and Molecular Biology, The George Washington University School of Medicine, Washington, D.C. Dr. Goldstein is also chairman of and chief scientific advisor to RegeneRx.